Background
==========

Idiopathic restless legs syndrome (RLS) is a common, chronic, and often underdiagnosed neurological sensorimotor disorder with detrimental effects on sleep, daytime functioning, and quality of life \[[@B1]-[@B3]\]. If RLS is severe and impairs activities of daily life, a long-term therapy has to be started and maintained over years or even life-time in numerous patients. Recent guidelines and practice recommendations favor the use of non-ergot dopamine agonists over the dopaminergic agent levodopa as first-line treatment for moderate to severe RLS \[[@B4]-[@B6]\]; however, only a few prospective trials investigated longer-term efficacy of open-label treatment with non-ergot dopamine agonists for 6 months \[[@B7]\] or 1 year \[[@B8]\]. No data have yet been published that report on stability of treatment efficacy, progress of tolerability problems, requirements for dosages of treatments, treatment complications such as augmentation or tolerance, or the overall retention rate on treatment during longer time periods. Here, we report the long-term efficacy and safety results of an ongoing trial after 2 years of rotigotine treatment.

The non-ergot dopamine agonist rotigotine shows activity at D~1~through to D~5~receptors and at selected serotonergic and adrenergic receptors \[[@B9]\]; it has been formulated as a silicone-based transdermal patch for once-daily application to provide continuous drug delivery and stable plasma concentrations over a 24-h period. Rotigotine transdermal patch has been successfully used in the treatment of Parkinson\'s disease (PD) \[[@B10],[@B11]\].

The transdermal delivery of a dopamine agonist is a new treatment option for RLS. Proof-of-concept for the rotigotine patch in patients with moderate to severe, idiopathic RLS was successfully demonstrated in a 1-week pilot trial \[[@B12]\], and efficacy and good tolerability was shown in a 6-week dose-finding trial \[[@B13]\] and in two 6-month randomized, placebo-controlled, fixed-dose trials conducted in Europe and the US \[[@B14],[@B15]\]. To assess long-term rotigotine safety and efficacy, patients completing the dose-finding trial \[[@B13]\] were offered the possibility of entering an open-label extension. Data from the initial placebo-controlled trial \[[@B13]\] and from the first year of the open-label follow-up \[[@B16]\] showed stable, clinically relevant improvements in all efficacy measures.

Methods
=======

Trial design
------------

This multicenter, multinational, single-arm, open-label extension trial (NCT00498186) started in July 2003 in 33 hospital outpatient units, sleep centers, or private neurology practices in three European countries (Austria, Germany, and Spain) and is still ongoing. It is being conducted according to the Declaration of Helsinki, Good Clinical Practice, and local regulations in each country. The trial protocol and amendments were reviewed and approved by a central institutional review board in Germany (Kommission für Ethik in der ärztlichen Forschung im Fachbereich Humanmedizin der Philipps-Universität Marburg) and in Austria (Ethikkommission der Medizinischen Universität Innsbruck). Review and approval was provided by regional institutional review boards in Spain. Written informed consent was obtained from all subjects prior to inclusion in the trial.

The trial design was described in the presentation of the first year trial data \[[@B16]\]. Briefly, following wash-out of the double-blind medication, rotigotine was up-titrated from a starting dose of 0.5 mg/24 h to a maximum dose of 4 mg/24 h according to the individual requirements of the patients with intermediate steps of 1 mg/24 h, 2 mg/24 h, or 3 mg/24 h. The patch was administered once-daily in the morning using rotating application sites within 14 days of treatment. During the trial, patients remained on their optimum dosage; however, dose adjustments were allowed for efficacy or tolerability reasons at the discretion of the investigators. Patients were withdrawn if higher doses than the maximum of 4 mg/24 h rotigotine were required. Visits throughout the maintenance phase were scheduled at 3-monthly intervals during the second trial year. In the event of premature discontinuation, a 1-week taper period and a 2-week surveillance period for safety follow-up was planned.

Outcome measures
----------------

Safety and tolerability were determined by adverse event (AE) documentation, patch application site assessment, changes in vital signs, body weight, 12-lead electrocardiogram (ECG), and safety laboratory parameters throughout the second trial year. \'Global rating of tolerability by the subject\' was assessed using a 5-point scale (1 = \'very good\' to 5 = \'very bad\'); Clinical Global Impressions (CGI) item 4 \'side effects\' (1 = none to 4 = outweighs therapeutic effect) \[[@B17]\] and the Epworth Sleepiness Scale (ESS) \[[@B18]\] were also evaluated. In addition, the rate of patients who completed the entire 2 years of long-term treatment (retention rate), as well as the rate and reasons of those patients who prematurely withdrew from the trial, were assessed. Patch adhesiveness was also evaluated using a patient questionnaire.

When the study was commenced, no validated tool for diagnosis and severity assessment for augmentation was available. Augmentation, could, however, be reported as a reason for dose adjustment.

Efficacy was evaluated using the total score of the International RLS Study Group Severity Rating scale (IRLS) \[[@B19]\], the RLS-6 scales to assess severity of RLS symptoms at different time periods, quality of sleep and daytime sleepiness \[[@B20]\], and the CGI to assess severity of symptoms, global change of condition, and therapeutic effect \[[@B17]\]. In addition to the analysis of changes from baseline in these variables, treatment responders were defined by a score improvement of at least 50% for the IRLS total score or CGI-1 at the end of the 2-year maintenance phase compared with baseline; a CGI-2 responder had a rating of \'much\' or \'very much improved\' at the end of year 2. A remitter was defined by an IRLS score of 10 or less at the end of year 2; the proportion of patients presenting with no symptoms at the end of year 2 (IRLS score = 0) was also calculated (symptom free). \'Global rating of efficacy by the subject\' was assessed using a 5-point scale (\'very good\' to \'very bad\') and quality of life (QoL) was evaluated with the total score of the QoL-RLS questionnaire \[[@B21]\].

Patients
--------

Patients completing the double-blind phase of the preceding dose-finding trial \[[@B13]\] were offered participation in this open-label extension. They were not permitted to participate if serious adverse events (SAEs) were ongoing that were suspected to be related to the previous trial medication, if severe application site disorders had occurred, or if they had not been compliant during the double-blind trial. A full description of the inclusion and exclusion criteria to enter the preceding trial can be found elsewhere \[[@B13]\].

Statistical analysis
--------------------

The present paper reports the 2-year interim data analysis of a 5-year trial. By nature of an interim analysis, some of the end of year 1 data in the present paper may differ slightly from the published year 1 analysis \[[@B16]\].

All patients treated with at least one dose of trial medication were included in the safety analysis; patients analyzed for efficacy had to have at least one efficacy value during the long-term extension trial (intention-to-treat \[ITT\]). Analyses included changes in variables from baseline to end of year 2 and changes from end of year 1 to end of year 2. If not otherwise stated, the baseline data of the preceding dose-finding trial for all patients entering the open-label trial (n = 295) were used \[[@B13]\]. All variables were analyzed descriptively based on observed cases per visit; the use of the \'Last Observation Carried Forward\' (LOCF) approach for some efficacy variables is indicated with the data. With respect to the validity of the efficacy variables, only those measures that were taken within 2 days of the last patch application were used.

Results
=======

Of a total of 295 patients entering the open-label trial, 220 patients completed the first trial year (retention rate 74.6%) and 191 patients completed the second trial year resulting in an overall retention rate of 64.7% after 2 years of treatment.

Mean age of the study population (n = 295) was 58.3 ± 10.1 years (range 22-75) at baseline with 66% of female gender. Patients had a long history of RLS symptoms; a large proportion had received pretreatment with dopaminergic drugs \[[@B13]\]. Baseline values of the IRLS total score (27.8 ± 5.9) indicated severe RLS on average; mean severity of daytime symptoms at rest in the RLS-6 scales was 4.9 ± 2.6 (range 0 = no symptoms, 10 = very severe symptoms).

Eighty-seven percent of the patients completing year 1 also completed year 2. Reasons for premature discontinuation during titration, the first, and second trial year are summarized in Table [1](#T1){ref-type="table"}.

###### 

Reasons for premature discontinuation

                              Number of patients (%)               
  --------------------------- ------------------------ ----------- -----------
  Patients withdrawn          5 (1.7)                  70 (24.1)   29 (13.2)
  Owing to                                                         
  Adverse event               4 (1.4)                  47 (16.2)   16 (7.3)
  Withdrawal of consent       1 (0.3)                  6 (2.1)     2 (0.9)
  Lack of efficacy            0                        10 (3.5)    7 (3.2)
  Protocol deviation          0                        4 (1.4)     0
  Unsatisfactory compliance   0                        2 (0.7)     2 (0.9)
  Lost to follow-up           0                        1 (0.3)     0
  Other reasons               0                        0           2 (0.9)

Treatment
---------

The mean duration of rotigotine exposure was 556 ± 256 days (median 700 days). The majority of the patients (94%) were compliant during maintenance (defined as ≥85% and ≤115% application of the planned number of patches). Withdrawal for noncompliance was documented for two patients in year 1 and two patients in year 2.

Individually optimized flexible doses ranged from 0.5 mg/24 h (2.5 cm^2^patch) to 4 mg/24 h (20 cm^2^patch). The most frequently applied dose at the end of year 2 was 4 mg/24 h (44.5% of all patients). The number of patients sufficiently treated with a dose of 0.5 or 1 mg/24 h (13.5%) decreased by 1.3% from year 1. The average daily dose during the maintenance phase showed a slight increase from 2.85 ± 1.15 mg/24 h in year 1 to 2.93 ± 1.14 mg/24 h in year 2. Figure [1](#F1){ref-type="fig"} shows the mean daily rotigotine dose over 24 months of maintenance. Dose adjustment was not required for 43.8% of patients during the 2-year maintenance; doses were adjusted once in 29% and twice in 16.9% of the patients. The remaining 10.3% needed 3 to 5 dose adjustments during maintenance. Of all patients entering year 2, 88% maintained their dose during year 2.

![**Mean daily rotigotine dose over the 2-year maintenance period (safety population)**.](1471-2377-10-86-1){#F1}

Safety outcomes
---------------

During the trial, 256 patients (87%) experienced at least one AE. The majority of AEs were mild or moderate in intensity; events were rated as severe in 22% of the patients.

Adverse events were documented for 75.2% of the patient population during the first trial year \[[@B16]\] and for 59.6% during the second year. Table [2](#T2){ref-type="table"} summarizes all incidences reported in more than 3% of all patients over the 2-year period. Application site disorders occurred most frequently; they were considered severe for 8.8% of the patients. More patients were affected by application site reactions during the first trial year (n = 100, 34.5%) whereas 16.4% (n = 36) reported them in the second year (25 patients \[8.5%\] had application site reactions ongoing from the preceding dose-finding study \[[@B13]\]). Discontinuation owing to any application site disorder was reported for 9.3% of patients (n = 27) in the first and 3.6% (n = 8) in the second trial year. The incidence of somnolence (2 cases), depression (5), syncope (1), insomnia (1), parasomnias (2), diarrhea (2), hypertension (4), and dry mouth (2) was low and sleep attacks, hallucination, dizziness, paraesthesia, and vomiting did not occur during year 2. During the second year, 21 patients (9.5%) experienced a total of 22 SAEs; none were considered to be related to trial medication. With the exception of localized osteoarthritis (4 patients), uterine leiomyoma (3), syncope (2), and goitre (2), all SAEs occurred only in single patients during the 2-year treatment period (for complete list of SAEs see Additional file [1](#S1){ref-type="supplementary-material"}). No deaths were reported in the 2-year study period.

###### 

Incidence of adverse events (AEs) reported in ≥3% of all patients during the 2-year maintenance (safety population)

                                      Number of patients (%)   
  ----------------------------------- ------------------------ ------------
  Patients with AEs                   218 (75.2)               131 (59.6)
  Number of AEs                       630                      263
                                                               
  Most frequent AEs^a^                                         
   Any application site disorder^b^   100 (34.5)               36 (16.4)
   Nasopharyngitis                    25 (8.6)                 9 (4.1)
   Back pain                          20 (6.9)                 10 (4.5)
   Erythema                           19 (6.6)                 2 (0.9)
   Nausea                             14 (4.8)                 2 (0.9)
   Pruritus                           11 (3.8)                 2 (0.9)
   Insomnia                           11 (3.8)                 1 (0.5)
   Hypertension                       10 (3.4)                 4 (1.8)
   Fatigue                            9 (3.1)                  5 (2.3)
   Bronchitis                         9 (3.1)                  5 (2.3)
   Sleep disorder                     9 (3.1)                  5 (2.3)
  Patients with serious AEs           21 (7.2)                 21 (9.5)
  Number of serious AEs               24                       22

^a^Incidence in ≥3% of all patients. ^b^Includes preferred terms application site erythema, application site reaction, application site pruritus, and other related terms with lower frequency (e.g., inflammation)

There were no major changes from double-blind baseline in any of the laboratory parameters including total iron and ferritin levels. There were no patients with any post-baseline QTc ≥500 ms or post-baseline increase in QTc ≥60 ms in the ECG during the trial period.

Tolerability outcomes
---------------------

The \'daytime tiredness\' score (RLS-6 scales) improved from a double-blind baseline score of 4.8 ± 2.6 by -2.6 ± 3.1 in the first year and by -2.2 ± 3.0 in the second year resulting in a total score of 2.5 ± 2.4 after 2 years of rotigotine treatment (Table [3](#T3){ref-type="table"}; negative changes in the table refer to improvements). The total ESS score improved from 6.7 ± 5.2 at double-blind baseline by -0.6 ± 4.6 after 2 years (Table [3](#T3){ref-type="table"}).

###### 

Improvement in efficacy over a 2-year maintenance treatment with transdermal rotigotine: Mean change from baseline; mean ± SD or number (%)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          Baseline of double-blind study   Change at end of year 1\   Change at end of year 1\   Change at end of year 2\   Change at end of year 2\                           
                                                                           (as observed)              (LOCF)                     (as observed)              (LOCF)                                             
  --------------------------------------- -------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ----- ----------------- -----------------
  IRLS total score                        295                              27.8 ± 5.9                 220                        -18.8 ± 8.8                -17.4 ± 9.9                190   -17.2 ± 9.2       -15.4 ± 10.3

  RLS-6                                                                                                                                                                                                        

   Satisfaction with sleep                293                              7.2 ± 2.5                  216                        -4.5 ± 3.4                 -4.1 ± 3.5                 190   -4.3 ± 3.3        -3.7 ± 3.4

   Severity at bedtime                    293                              6.0 ± 3.0                  215                        -4.6 ± 3.2                 -4.2 ± 3.3                 189   -4.0 ± 3.1        -3.8 ± 3.2

   Severity during the night              294                              6.8 ± 2.7                  216                        -5.2 ± 3.0                 -4.9 ± 3.1                 190   -4.9 ± 3.0        -4.5 ± 3.2

   Severity during the day when resting   293                              4.9 ± 2.6                  216                        -3.4 ± 2.6                 -3.4 ± 2.7                 190   -2.9 ± 2.7        -2.9 ± 3.0

   Severity during the day when active    294                              1.9 ± 2.0                  217                        -1.4 ± 1.9                 -1.5 ± 2.0                 190   -1.2 ± 2.0        -1.2 ± 2.2

   Daytime tiredness or sleepiness        294                              4.8 ± 2.6                  217                        -2.8 ± 2.9                 -2.6 ± 3.1                 190   -2.4 ± 2.7        -2.2 ± 3.0

  CGI-1 (severity of illness)             295                              5.1 ± 0.9                  217                        -2.9 ± 1.2                 -2.8 ± 1.3                 191   -2.8 ± 1.2        -2.6 ± 1.4

  QoL-RLS total score                     273                              30.2 ± 10.4                200                        -19.1 ± 12.2               -17.7 ± 13.2               178   -17.7 ± 12.8^a^   -15.8 ± 13.8^a^

  ESS total score                         289                              6.7 ± 5.2                  215                        -1.5 ± 4.5                 n.d.                       185   -0.8 ± 4.6        -0.6 ± 4.6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^after 21 months of maintenance

Based on CGI tolerability rating, a total of 70% of the 220 patients completing year 1 and 71% of the 191 patients completing the second trial year were not impaired by side effects at all; 28.1% of the year 1 completers and 28.3% of the year 2 completers reported that side effects did not significantly interfere with their daily activities. At the end of the 2-year period, a \'significant interference\' and \'side effects outweighing efficacy\' were reported in 13% and 6.8%, respectively, of all patients who had entered the trial.

Rotigotine tolerability after 2 years of treatment was rated as \'very good\' or \'good\' by 77% of all patients (n = 295). Seventeen patients (5.8%) described tolerability as \'very bad\'.

Patch adhesiveness and ease of removal were considered moderate (15%/4.5%), good (50%/58%), or excellent (31%/34%) by most patients treated in year 2 (n = 220).

Efficacy
--------

Rotigotine transdermal patch rapidly improved the IRLS severity rating; the baseline sum score of 27.8 ± 5.9 was reduced by 18.8 ± 8.6 during the 4-week titration phase of the open-label trial (Figure [2](#F2){ref-type="fig"}). This result is comparable to the data recorded during rotigotine titration in the preceding double-blind, placebo-controlled trial \[[@B13]\]. Figure [3](#F3){ref-type="fig"} shows the changes in IRLS severity over 2 years of rotigotine treatment. At month 12 and month 24, mean IRLS sum scores of 8.7 ± 8.0 and 10.3 ± 9.3, respectively, were calculated. Mean reduction after 2 years of rotigotine maintenance treatment was 15.4 ± 10.3 for all patients entering this extension trial (n = 295, LOCF) and 17.2 ± 9.2 for all patients completing the 2-year period (n = 190). CGI-1 and RLS-6 daytime at rest scores closely follow this pattern (Figure [2](#F2){ref-type="fig"}). All other efficacy variables also improved over the 2-year period (Table [3](#T3){ref-type="table"}) and remained stable during the second year when compared with the year 1 results \[[@B16]\]. Responder rates indicate that the majority of patients benefited from rotigotine treatment (Table [4](#T4){ref-type="table"}). Overall, 30% of all patients who completed the 2-year treatment were free of symptoms according to IRLS (total score = 0) and 30% were free of symptoms according to CGI-1 (not ill at all). Therapeutic efficacy of rotigotine was rated as \'good\' to \'very good\' in 95% (n = 209) of year 1 completers and 89% (n = 170) of year 2 completers.

![**Mean IRLS total score, CGI item 1 (severity of illness), and RLS-6 item 4 (severity during the day at rest) scores over 2 years of rotigotine maintenance treatment (data as observed)**. B, baseline; CGI, Clinical Global Impression; IRLS, International RLS Severity Scale; RLS, restless legs syndrome S, start of maintenance phase.](1471-2377-10-86-2){#F2}

![**Changes in IRLS severity over 2 years of rotigotine maintenance treatment (data as observed)**.](1471-2377-10-86-3){#F3}

###### 

Improvement in efficacy over a 2-year maintenance treatment with transdermal rotigotine: responder and remitter rates compared with baseline

                                                         End of year 1   End of year 2            
  ------------------------------------------------------ --------------- --------------- -------- -----
  IRLS total score                                                                                
   Responder (≥50% improvement)                          75%             68%             65%      79%
   Remitter (total score ≤10)                            60%             54%             53%      62%
   Symptom-free (total score = 0)                        30%             25%             30%      32%
  CGI-1 responder (≥50% improvement)                     79%             72%             75%^a^   65%
  CGI-2 responder (\'much\' or \'very much\' improved)   97%             89%             95%^a^   85%

^a^n = 191

CGI, Clinical Global Impression; ESS, Epworth Sleepiness Scale; IRLS, International RLS Severity Scale; QoL, quality of life; RLS, restless legs syndrome

Range of scales: IRLS: 0 to 40 (= severe), RLS-6: 0 to 10 (= severe); CGI-1: 1 to 7 (= extremely severe), QoL-RLS: 0 to 60 (= severe impairment)

Discussion
==========

Rotigotine transdermal patch is the first transdermally applied dopamine agonist for the treatment of symptoms of RLS and covers a 24-h period with a single administration. The continuous rotigotine delivery seems to translate into long-term benefits for patients moderately to severely affected by RLS. Over a period of 2 years, a rotigotine dose range of 0.5 mg/24 h to 4 mg/24 h provided sustained relief from symptoms with a very good tolerability and a favorable safety profile.

Rotigotine dose levels remained quite stable from the first to the second trial year with only a small dose increase of 2.9% for a mean daily dose of 2.93 mg/24 h after 2 years of treatment. The most frequently applied rotigotine dose at the end of 2 years was 4 mg/24 h (44.5% of patients); 13.5% were sufficiently treated with a low dose of 0.5 or 1.0 mg/24 h. In the preceding 6-week dose-finding trial with a fixed dosing schedule, the 4 mg/24 h dose did not show an additional benefit compared with 3 mg/24 h over the 6-week treatment period. The likely therapeutic window for the treatment of idiopathic moderate to severe RLS was thus established as ranging from 1 mg/24 h to 3 mg/24 h \[[@B13]\]. The distribution of individual rotigotine doses in this trial supports the opinion of most RLS experts that dose selection has to be adjusted according to efficacy and tolerability experiences of each individual patient and dosages of rotigotine both lower or higher than the recommended doses of 1 mg/24 h or 3 mg/24 h may be appropriate during long-term rotigotine therapy.

Discontinuation rates owing to a lack or loss of efficacy through 2 years of rotigotine treatment were low (5.8%). No comparable data for this length of study duration are available for other dopamine agonists. Discontinuation rates for studies of shorter duration are as follows: 3.3% within 6 months \[[@B22]\] and 7.9% within 30 weeks \[[@B23]\] of treatment with cabergoline, and 3.5% within 52 weeks of treatment with ropinirole \[[@B8]\]. Open-label treatment with pramipexole for 26 weeks did not lead to withdrawal for efficacy reasons \[[@B7]\].

Augmentation, the main complication of long-term dopaminergic treatment in RLS \[[@B24]\], is mainly characterized by an earlier appearance of RLS symptoms in the day and an overall increase in the severity of RLS symptoms. Augmentation was given as the reason for seven dose adjustments - a low occurrence of 2.4% over 2 years. In the absence of any validated diagnostic tool for the diagnosis of augmentation at the start of the study, a detailed retrospective analysis by an expert panel is planned following completion of the full 5-year observation period.

Known dopaminergic side effects such as nausea and fatigue occurred mainly during titration and the first study year \[[@B16]\]. Incidences during the first year were similar to the rates reported in open-label long-term trials for cabergoline (6 months) \[[@B22]\] and pramipexole (26 weeks) \[[@B7]\] but lower than for ropinirole (52 weeks) \[[@B8]\]. During the second year, only two cases of nausea and five cases of fatigue were documented, and vomiting was not reported as an AE. The incidence of somnolence was also lower in year 2 (two cases compared with five cases in year 1), and hallucinations, dizziness, and sleep attacks were not reported.

As expected with a transdermal application, skin reactions were common with higher rates in the first (34.5%, 100/290 patients) compared with the second (16.4%, 36/220) trial year. Most cases were mild to moderate in intensity. However, a proportion of patients discontinued owing to application site problems: 27 patients left the study in year 1 and 8 patients in year 2. Similar or higher discontinuation rates of patch treatments were reported for other indications \[[@B25],[@B26]\].

Investigators noted \'much\' and \'very much\' improvement of RLS in 95% of all patients who had entered this open-label extension. The severity of the condition as measured with the IRLS already improved during the titration period, remained stable during the first trial year \[[@B16]\] and only slightly increased during the second year. More than half of the patients completing the study were regarded as remitters (53%) and 30% were symptom-free after 2 years of rotigotine treatment. Responder rates underline the sustained, long-term benefit of the rotigotine transdermal patch. The improvement in QoL paralleled by the improvement of RLS symptoms during the night as well as during the day (as shown in the RLS-6 scales) supports the benefit of delivery of rotigotine over 24 hours in the treatment of RLS.

The good long-term efficacy and safety profile of transdermal rotigotine resulted in high retention rates: after 2 trial years it was 66%, and 87% of the patients entering the second year completed 2 years of maintenance. Compliance in the second year was still 92% and the majority of the patients rated tolerability and efficacy of the treatment as \'good\' or \'very good\'. Treatment satisfaction is also underlined by the QoL-RLS score which was improved by 50% at the end of the 2-year follow-up from baseline of the double-blind trial \[[@B13]\].

In interpreting these long-term open-label data, it is important to note the limitation presented by the absence of a comparator arm; however, inclusion of a placebo group for 2 years of follow-up is inappropriate both practically and ethically. In the preceding 6-week, double-blind study a reduction in IRLS score of 9.2 points from baseline was observed in the group of patients randomized to placebo \[[@B13]\]. The 15- to 17-point reduction observed with open-label rotigotine is consistent with the reductions achieved with rotigotine doses of 1-4 mg/24 h during the double-blind study. Although these open-label data support the assumption of a symptomatic benefit over a 2-year period, the net effect on IRLS reduction with rotigotine is likely less than the 15-17 points reported here.

Putting both efficacy and tolerability results into perspective, the 2-year data of the rotigotine trial indicate a selection process: patients who do not tolerate either the dopamine agonist or the patch administration, or both, generally discontinue treatment during the first year of therapy. Perceived loss of efficacy is not a major issue during long-term therapy with rotigotine in the great majority of the patients. Thus a high number of patients who stayed on therapy benefited from rotigotine as expressed in the fact that 30% of patients (57 of 190 patients) were free of symptoms after 2 years.

Conclusions
===========

The findings of this trial suggest that long-term administration of rotigotine transdermal patch is generally well tolerated and an efficacious treatment option for patients with moderate to severe RLS. The treatment markedly improved RLS symptoms and quality of life of the patients.
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